Drug Trial Radar · NCT04332653
NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Mar 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
215
Actual
Start
Jun 10, 2020
Primary completion
Nov 22, 2024
Study completion Jan 13, 2025
Sponsor
- Lead sponsor
- NeoImmuneTechIndustry
- Sponsor type
- Industry
- Collaborators
- Merck Sharp and Dohme LLC, Rahway, NJ, USA
- First posted
- Apr 3, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purposes of Phase 1b of this study are to determine the following in participants with advanced solid tumors: * Safety and tolerability of NT-I7 in combination with pembrolizumab * Maximum Tolerated Dose (MTD) and/or the Recommended Phase 2 Dose (RP2D) The main purpose of Phase 2a of this study is to assess the preliminary anti-tumor activity of NT-I7 in combination with pembrolizumab in participants with checkpoint inhibitor (CPI) treated and naïve relapsed and refractory (R/R) tumors. The main purpose of the Biomarker Cohort is to assess a potential correlation between tumor infiltrating lymphocytes (TILs) and clinical benefits in participants with CPI-naïve R/R ovarian cancer (OC).
Conditions
- Any Advanced Solid Tumors
- Triple Negative Breast Cancer
- Non Small Cell Lung Cancer
- Small Cell Lung Cancer
- Microsatellite Stable Colorectal Cancer
- Pancreatic Cancer
- Ovarian Cancer
Interventions
NT-I7Drug
Administered by intramuscular (IM) injection
pembrolizumab (KEYTRUDA®)Drug
Administered by intravenous (IV) injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1b: Number of Participants Who Experienced Treatment Emergent Adverse Events (TEAEs), Serious AEs (SAEs), Trial Treatment-related TEAEs and Trial Treatment-related SAEsTime frame: Up to 2 years and 3 months
- Phase 1b: Number of Participants Who Experienced a Dose Limiting Toxicity (DLT)Time frame: Up to 21 days
- Phase 2a (Arms I to Va): Objective Response Rate (ORR)Time frame: Up to 2 years
- Biomarker Cohort: Percentage of Area Occupied by Tumor-Infiltrating Lymphocytes (TILs)Time frame: Pre-treatment and post-treatment (maximum duration of treatment of approximately 2 years)
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Moffit Cancer Center
Tampa, Florida
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan
Washington University School of Medicine in St. Louis
St Louis, Missouri
Duke University Medical Center
Durham, North Carolina
Fox Chase Cancer Center
Philadelphia, Pennsylvania
Sarah Cannon Research Institute
Nashville, Tennessee
Mary Crowley Cancer Research
Dallas, Texas
MD Anderson Cancer Center
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.